Effectdossier · gearchiveerd kwartaal
TSHA
Taysha Gene Therapies, Inc. · Healthcare · Biotechnology
18Gevolgde houders
-1Δ houders
108.64MGehouden aandelen
$355.25MGerapporteerde waarde
+0Nieuwe posities
−1Uitstappen
Momentum-inputs (vergelijkbare managers):
breedte van houders -5.3% ·
aandelenstroom +9.6% ·
netto nieuwe posities -5.6%
— formule
Geconcentreerde accumulatie — stijgende aandelen bij minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
Eigendom in de tijd
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 85 | +6 | 146.63M | $997.83M | +12 | −5 |
| Q1 2026 | 81 | -9 | 130.93M | $584.01M | +4 | −14 |
| Q4 2025 | 90 | 0 | 135.71M | $746.41M | +2 | −1 |
| Q3 2025 | 18 | -1 | 108.64M | $355.25M | — | −1 |
| Q2 2025 | 16 | +5 | 65.80M | $152.01M | +5 | — |
| Q1 2025 | 8 | -4 | 14.26M | $19.83M | +1 | −5 |
| Q4 2024 | 12 | +5 | 19.11M | $33.06M | +5 | — |
| Q3 2024 | 6 | 0 | 7.50M | $15.08M | +2 | −2 |
| Q2 2024 | 6 | — | 5.37M | $12.04M | — | — |
Wie het bezit · Q3 2025
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Morgan Stanley ✦ | 19.31M | — | $63.14M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Morgan Stanley ✦ | 19.31M | — | $63.14M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Morgan Stanley ✦ | 19.31M | — | $63.14M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Morgan Stanley ✦ | 19.31M | — | $63.14M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Morgan Stanley ✦ | 19.31M | — | $63.14M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Morgan Stanley ✦ | 19.31M | — | $63.14M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Morgan Stanley ✦ | 19.31M | — | $63.14M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | BlackRock ✦ (passief) | 16.36M | +23.0% | $53.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | BlackRock ✦ (passief) | 16.36M | +23.0% | $53.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | BlackRock ✦ (passief) | 16.36M | +23.0% | $53.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | BlackRock ✦ (passief) | 16.36M | +23.0% | $53.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | BlackRock ✦ (passief) | 16.36M | +23.0% | $53.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | BlackRock ✦ (passief) | 16.36M | +23.0% | $53.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | BlackRock ✦ (passief) | 16.36M | +23.0% | $53.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | BlackRock ✦ (passief) | 16.36M | +23.0% | $53.51M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | Fidelity (FMR) ✦ | 14.59M | -6.6% | $47.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Fidelity (FMR) ✦ | 14.59M | -6.6% | $47.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | Fidelity (FMR) ✦ | 14.59M | -6.6% | $47.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Goldman Sachs Group ✦ | 13.38M | — | $43.76M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Goldman Sachs Group ✦ | 13.38M | — | $43.76M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | The Vanguard Group ✦ (passief) | 12.85M | +17.9% | $42.02M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 22 | The Vanguard Group ✦ (passief) | 12.85M | +17.9% | $42.02M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 23 | The Vanguard Group ✦ (passief) | 12.85M | +17.9% | $42.02M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 24 | Point72 Asset Management ✦ | 7.33M | +0.2% | $23.97M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 25 | State Street Global Advisors ✦ (passief) | 7.24M | +40.8% | $23.66M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 26 | Geode Capital Management ✦ (passief) | 5.17M | +36.4% | $16.92M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 27 | Geode Capital Management ✦ (passief) | 5.17M | +36.4% | $16.92M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 28 | Millennium Management ✦ | 4.03M | +37.1% | $13.17M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 29 | Adage Capital Partners ✦ | 3.33M | -31.2% | $10.88M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 30 | D. E. Shaw & Co. ✦ | 2.71M | +574.1% | $8.85M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 31 | JPMorgan Chase ✦ | 592.49K | — | $1.94M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | JPMorgan Chase ✦ | 592.49K | — | $1.94M | 0.0% | n/c | 1 | SEC ↗ |
| 33 | JPMorgan Chase ✦ | 592.49K | — | $1.94M | 0.0% | n/c | 1 | SEC ↗ |
| 34 | JPMorgan Chase ✦ | 592.49K | — | $1.94M | 0.0% | n/c | 1 | SEC ↗ |
| 35 | JPMorgan Chase ✦ | 592.49K | — | $1.94M | 0.0% | n/c | 1 | SEC ↗ |
| 36 | JPMorgan Chase ✦ | 592.49K | — | $1.94M | 0.0% | n/c | 1 | SEC ↗ |
| 37 | Wellington Management ✦ | 568.01K | -10.7% | $1.86M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 38 | Wellington Management ✦ | 568.01K | -10.7% | $1.86M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 39 | Wellington Management ✦ | 568.01K | -10.7% | $1.86M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 40 | Marshall Wace ✦ | 476.87K | +499.9% | $1.56M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 41 | Citadel Advisors ✦ | 367.31K | -30.6% | $1.20M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 42 | Citadel Advisors ✦ | 367.31K | -30.6% | $1.20M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 43 | AQR Capital Management ✦ | 151.00K | +11.2% | $493,769 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 44 | AQR Capital Management ✦ | 151.00K | +11.2% | $493,769 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 45 | AQR Capital Management ✦ | 151.00K | +11.2% | $493,769 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 46 | AQR Capital Management ✦ | 151.00K | +11.2% | $493,769 | 0.0% | ▲ Add | 5 | SEC ↗ |
| 47 | T. Rowe Price ✦ | 113.83K | +34.5% | $373,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 48 | Two Sigma Investments ✦ | 66.11K | +102.3% | $216,163 | 0.0% | ▲ Add | 2 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Renaissance Technologies | $126,819 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 190 houders, 265.00M aandelen, $1.21B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Vaak gezamenlijk in bezit
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Herkomst: Eigendom op basis van geparseerde 13F common-stockposities (gevolgde universum, vergelijkbare sets voor wijzigingen); insider-rijen afkomstig van formulieren 3/4/5; belangen uit Schedules 13D/13G; elke indiening verwijst naar het origineel op SEC EDGAR.
Rapportageperiode: Q3 2025 ·
Methodologie ·
Verkrijg dit via de API